Fig. 1From: Rationale and study design of a randomized, placebo-controlled, double-blind phase 2b trial to evaluate efficacy, safety, and tolerability of an oral glutaminyl cyclase inhibitor varoglutamstat (PQ912) in study participants with MCI and mild AD—VIVIADOverview of study design. Coding test, WAIS-IV coding test; MMSE, Mini Mental State Examination; NTB, Neuropsychological Test Battery; WLA, Winterlight Language Assessment; A-IADL-Q, Amsterdam Instrumental of Activities of Daily Living QuestionnaireBack to article page